Header Logo

Connection

Joan Merrill to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Joan Merrill has written about Treatment Outcome.
Joan Merrill
Connection Strength
1.677
Treatment Outcome
  1. Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology (Oxford). 2021 11 03; 60(11):5379-5389.
    View in: PubMed
    Score: 0.125
  2. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology (Oxford). 2020 10 01; 59(10):2930-2938.
    View in: PubMed
    Score: 0.116
  3. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 06; 77(6):883-889.
    View in: PubMed
    Score: 0.097
  4. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheumatol. 2018 02; 70(2):266-276.
    View in: PubMed
    Score: 0.096
  5. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb; 75(2):332-40.
    View in: PubMed
    Score: 0.081
  6. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014 Feb; 66(2):379-89.
    View in: PubMed
    Score: 0.073
  7. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Oct; 64(10):3364-73.
    View in: PubMed
    Score: 0.066
  8. Treatment of systemic lupus erythematosus: a 2012 update. Bull NYU Hosp Jt Dis. 2012; 70(3):172-6.
    View in: PubMed
    Score: 0.063
  9. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov; 70(11):1905-13.
    View in: PubMed
    Score: 0.061
  10. Ending the 50-year drought of FDA drug approval for SLE. Bull NYU Hosp Jt Dis. 2011; 69(3):238-42.
    View in: PubMed
    Score: 0.059
  11. Rituximab: wanted dead or alive... Arthritis Rheum. 2010 Aug; 62(8):2188-91.
    View in: PubMed
    Score: 0.057
  12. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan; 62(1):222-33.
    View in: PubMed
    Score: 0.055
  13. Clinical trials for lupus--are we there yet? Bull NYU Hosp Jt Dis. 2009; 67(3):267-70.
    View in: PubMed
    Score: 0.051
  14. Catastrophic antiphospholipid syndrome. Nat Clin Pract Rheumatol. 2006 Feb; 2(2):81-9.
    View in: PubMed
    Score: 0.042
  15. Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2022 Nov; 74(11):1822-1828.
    View in: PubMed
    Score: 0.033
  16. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Ann Rheum Dis. 2022 07; 81(7):962-969.
    View in: PubMed
    Score: 0.032
  17. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022 07; 81(7):951-961.
    View in: PubMed
    Score: 0.032
  18. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022 03; 81(3):370-378.
    View in: PubMed
    Score: 0.031
  19. Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken). 2020 12; 72(12):1800-1808.
    View in: PubMed
    Score: 0.029
  20. Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus. J Am Acad Dermatol. 2021 Jun; 84(6):1562-1567.
    View in: PubMed
    Score: 0.028
  21. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 07; 71(7):1125-1134.
    View in: PubMed
    Score: 0.026
  22. Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Ann Rheum Dis. 2019 07; 78(7):1010-1012.
    View in: PubMed
    Score: 0.026
  23. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. Arthritis Rheumatol. 2018 07; 70(7):1071-1076.
    View in: PubMed
    Score: 0.025
  24. Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. Rheumatology (Oxford). 2018 01 01; 57(1):125-133.
    View in: PubMed
    Score: 0.024
  25. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis. J Rheumatol. 2018 04; 45(4):456-464.
    View in: PubMed
    Score: 0.024
  26. Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design. Arthritis Rheumatol. 2017 04; 69(4):785-790.
    View in: PubMed
    Score: 0.023
  27. Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study. Arthritis Care Res (Hoboken). 2016 Apr; 68(4):534-43.
    View in: PubMed
    Score: 0.021
  28. Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Nov; 75(11):1909-1916.
    View in: PubMed
    Score: 0.021
  29. Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015 Aug 20; 17:215.
    View in: PubMed
    Score: 0.020
  30. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-a) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016 Jan; 75(1):196-202.
    View in: PubMed
    Score: 0.020
  31. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Nov; 66(11):1653-61.
    View in: PubMed
    Score: 0.019
  32. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb; 41(2):300-9.
    View in: PubMed
    Score: 0.018
  33. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol. 2013 Nov; 40(11):1875-80.
    View in: PubMed
    Score: 0.018
  34. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol. 2013 May; 40(5):579-89.
    View in: PubMed
    Score: 0.017
  35. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012 Nov; 71(11):1833-8.
    View in: PubMed
    Score: 0.016
  36. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum. 2012 Aug; 42(1):56-65.
    View in: PubMed
    Score: 0.016
  37. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec; 63(12):3918-30.
    View in: PubMed
    Score: 0.016
  38. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011 Jun; 70(6):961-7.
    View in: PubMed
    Score: 0.015
  39. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15; 61(9):1168-78.
    View in: PubMed
    Score: 0.013
  40. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15; 61(9):1143-51.
    View in: PubMed
    Score: 0.013
  41. Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. Rheumatology (Oxford). 2009 May; 48(5):513-9.
    View in: PubMed
    Score: 0.013
  42. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 Nov 24; 353(21):2219-28.
    View in: PubMed
    Score: 0.010
  43. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004 Sep; 50(9):2858-68.
    View in: PubMed
    Score: 0.009
  44. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec; 46(12):3251-8.
    View in: PubMed
    Score: 0.008
  45. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002 Jul; 46(7):1820-9.
    View in: PubMed
    Score: 0.008
  46. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum. 2001 Jun; 44(6):1466-7.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.